Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter co... by Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yoshihisa Mimura, Yosuke Sugiyama, Rei Unno, Atsushi Okada, Takahiro Yasui, Yoko Furukawa-Hibi

Subjects: Get full text

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis by Bowen Dai, Jiaping Jiang, Xiaoyu Yu, Haihua Zhan, Zhengchuan Hu

Subjects: Get full text

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma by Maki Todo, Yodo Gatate, Shintaro Nakano, Go Kaneko, Masayuki Hagiwara, Takayuki Takahashi, Yuta Umezawa, Genji Ueda, Shiho Ishikawa, Yoshinori Makino, Masafumi Oyama, Suguru Shirotake

Subjects: “…Nivolumab and ipilimumab…”
Get full text

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer by Yat-Fung Chow, Hou-Hsuan Cheng, Ming-Huang Chen

Subjects: Get full text

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors by Philippe Rochigneux, Philippe Rochigneux, Alexandre Bertucci, Elika Loir, Alexia Mattei, Danielle Robert, Michael Dassa, Brice Chanez, Mikael Ebbo, Lea Gaigne, Anne Sophie Chretien, Giovanni Corazza, Giovanni Corazza, Nicolas Schleinitz

Subjects: Get full text

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE by N. V. Zhukova, R. V. Orlova, N. Yu. Antimonik, S. I. Kutukova, N. P. Belyak, N. V. Popova, S. P. Erdniev

Subjects: Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

Subjects: Get full text

5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas by I-Wei Ho, Nai-Jung Chiang, Jiun-I Lai, Peter Mu-Hsin Chang, San-Chi Chen, Yi-Ping Hung, Ming-Huang Chen

Subjects: Get full text